Validated Green UV Spectrophotometric Approach for the Simultaneous Estimation of Torsemide and Eplerenone in Pharmaceutical Formulationusing Green Assessment Tools

Introduction: The combination of Torsemide (TOR) and Eplerenone (EPL) is clinically important for efficacy, safety, and risk imbalance in cardiovascular treatment. Simultaneous analysis of multiple drugs in combination dosage forms ensures patient safety and offers significant analytical challenges due to overlapping spectra. This study presents a new green, accurate, and reproducible UV spectrophotometric method using the isosbestic technique to estimate TOR and EPL drugs in a combination dosage form. Material and Methods: This method involves the identification of an isosbestic point, a wavelength at which the absorbance of two components remains unchanged despite their concentration ratio. The technique measures absorbance at λmax 290 nm and the isosbestic point (Aiso) 258.6 nm in the range of 5-30 μg/ml to determine the concentration of TOR and the total mixture of TOR and EPL, respectively. Green solvents were used to perform this study. Results: Method validation results obey the ICH guidelines. Recovery studies verify accuracy, yielding outcomes in the range of 98%-102 %, including low LOD (0.49 μg/ml of TOR and 0.53 μg/ml of EPL) and LOQ (1.63 μg/ml of TOR and 1.79 μg/ml of EPL) readings, which show the method’s sensitivity. According to the Analytical Eco-Scale and Complex Modified Green Analytical Procedure Index (ComplexMoGAPI), scores show an excellent green profile for the analyst and environment. Discussion: The method results obtained from the isosbestic analysis method exhibited exceptional precision, accuracy, and sensitivity. Green chemistry metrics stated that the method offers an eco-friendly approach for the simultaneous analysis of multiple components. Conclusion: The established green UV spectrophotometric method is a cost-effective and efficient analytical tool for the simultaneous quantification and routine quality assessment of TOR and EPL in combined dosage forms.